Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

VCYT - Veracyte Inc


IEX Last Trade
31.56
-0.380   -1.204%

Share volume: 676,769
Last Updated: Fri 30 Aug 2024 09:59:58 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$31.94
-0.38
-1.19%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
9%
Profitability 0%
Dept financing 2%
Liquidity 72%
Performance 4%
Company vs Stock growth
vs
Performance
5 Days
-1.41%
1 Month
33.86%
3 Months
50.31%
6 Months
32.73%
1 Year
19.19%
2 Year
54.43%
Key data
Stock price
$31.56
P/E Ratio 
-44.84
DAY RANGE
N/A - $32.15
EPS 
-$0.73
52 WEEK RANGE
$18.61 - $33.33
52 WEEK CHANGE
$0.18
MARKET CAP 
2.423 B
YIELD 
N/A
SHARES OUTSTANDING 
76.812 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
BETA 
1.94
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$606,780
AVERAGE 30 VOLUME 
$1,156,022
Company detail
CEO: Bonnie Anderson
Region: US
Website: https://www.veracyte.com/
Employees: 557
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

veracyte is a pioneering genomic diagnostics company. our tests are dramatically improving clinical outcomes for patients by resolving inconclusive results from traditional diagnostic methods. we ask the right questions to resolve ambiguity and bring assurance to light, rendering tens of thousands of costly and unnecessary surgeries truly unnecessary. we are giving patients a clearer path forward. through scientific rigor we employ the best tools, best science and best minds to create tests that enable a more accurate diagnosis without the need for risky, costly and often unnecessary surgery. veracyte consistently brings to bear evidence that is unprecedented in genomic tests, thereby changing today's clinical practice standards. we are making a difference in the lives of physicians and patients. we are doing something real. .

Recent news